Ve­rastem takes Ab­b­Vie’s blood can­cer castoff to the FDA

A blood can­cer drug that’s passed through the hands of sev­er­al com­pa­nies – dis­ap­point­ing drug­mak­ers along the way – is fi­nal­ly head­ed to the FDA. Ve­rastem $VSTM, a com­pa­ny near Boston, has filed for ap­proval of du­velis­ib, a pill that blocks the well-known can­cer tar­get PI3 ki­nas­es.

The drug is meant as a treat­ment for pa­tients who have blood can­cers chron­ic lym­pho­cyt­ic leukemia, small lym­pho­cyt­ic lym­phoma, or fol­lic­u­lar lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER